Advantages and disadvantages of biodegradable platforms in drug eluting stents

Table 4 Comparison of baseline characteristics and follow up angiographic and clinical results from the randomized LEADERS[28] and EUCATAX[39] trials

Patients characteristics	BioMatrix	Cypher	EucaTax	P values
No. of patients	857	850	211
Age (yr)	65 ± 11	65 ± 11	63.8 ± 10.2	0.32
Male gender	75.0	75.0	83.4	0.62
Hypertension	74.0	73.0	64.0	0.46
Diabetes mellitus	26.0	23.0	23.2	0.49
Hypercholesterolemia	65.0	68.0	56.9	0.36
Smoking	24.0	25.0	21.3	0.68
Previous MI	32.0	33.0	20.4	0.02
Previous PCI	36.0	37.0	35.5	0.93
Multi vessel disease	37.0	32.0	55.0	< 0.001
Clinical presentation
Acute coronary syndrome	55.0	56.0	59.7	0.80
Lesions per patient
> 1 lesion	29.0	22.0	26.1	0.09
Small vessels1	68.0	69.0	60.3	0.45
Procedural characteristics
Stents per lesion	1.3 ± 0.7	1.3 ± 0.7	1.36 ± 0.5	0.38
Stent length per lesion (mm)	24.7 ± 15.5	24.6 ± 14.8	21.7 ± 5.6	0.006
Angiographic follow-up
In-stent late loss	0.08 ± 0.4	0.15 ± 0.4	0.52 ± 0.6	< 0.001
Stent thrombosis2
Overall stent thrombosis	3.6	3.3	1.4	0.28
Definite ST
0-30 d	1.6	1.6	0.5	0.43
> 30 d-12 mo	0.4	0.5	0.9	0.52
0 d-12 mo	2.0	2.0	1.4	0.82
Efficacy endpoints at 12 mo
Any TLR	6.5	7.4	6.1	0.63
Any TVR	7.8	9.9	8.2	0.23
Safety endpoints at 12 mo
All causes of death	3.2	3.3	2.4	0.80
Cardiac death	2.1	2.7	1.9	0.66
Myocardial infarction	5.8	4.6	2.8	0.11
Cardiac death or MI	6.7	6.6	4.7	0.46

¹Small vessel was defined as any vessel diameter with less than 2.75 mm;

²Stent thrombosis definition by the Academic Research Consortium. MI: Myocardial infarction; PCI: Percutaneous coronary intervention; RVD: Reference vessel diameter; QCA: Quantitative coronary angiography; MLD: Minimal luminal diameter; DS: Diameter stenosis; TLR: Target lesion revascularization; TVR: Target vessel revascularization.